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1. BACKGROUND {#cam41879-sec-0005}
=============

Infections with human papillomavirus (HPV) types 16 and 18 are responsible for approximately 70% of invasive cervical cancers.[1](#cam41879-bib-0001){ref-type="ref"} While most infections clear on their own, some develop into precancerous lesions and cervical cancer.

Previous studies have shown that many women with incident HPV‐16 or HPV‐18 infections develop serum antibodies of the corresponding type of HPV.[2](#cam41879-bib-0002){ref-type="ref"}, [3](#cam41879-bib-0003){ref-type="ref"}, [4](#cam41879-bib-0004){ref-type="ref"}, [5](#cam41879-bib-0005){ref-type="ref"}, [6](#cam41879-bib-0006){ref-type="ref"}, [7](#cam41879-bib-0007){ref-type="ref"}, [8](#cam41879-bib-0008){ref-type="ref"} These naturally acquired antibodies can remain detectable for at least 4‐5 years after the initial infection.[9](#cam41879-bib-0009){ref-type="ref"} Whether or not these naturally acquired antibodies protect against future infection remains debatable.[10](#cam41879-bib-0010){ref-type="ref"}, [11](#cam41879-bib-0011){ref-type="ref"}, [12](#cam41879-bib-0012){ref-type="ref"}, [13](#cam41879-bib-0013){ref-type="ref"}, [14](#cam41879-bib-0014){ref-type="ref"}, [15](#cam41879-bib-0015){ref-type="ref"}, [16](#cam41879-bib-0016){ref-type="ref"}, [17](#cam41879-bib-0017){ref-type="ref"}, [18](#cam41879-bib-0018){ref-type="ref"}

Risk of incident HPV infections in adult women is positively associated with new sexual partners and with the lifetime number of sexual partners.[19](#cam41879-bib-0019){ref-type="ref"}, [20](#cam41879-bib-0020){ref-type="ref"} In older women, both new viral acquisition and intermittent detections of HPV from past HPV exposures are likely to account for what has been classified as apparent new HPV infections. In women 30‐50 years of age, factors associated with repeat HPV detection have been shown to be comparable in short‐term and longer‐term studies, suggesting association between short‐term repeat detection and long‐term persistence.[21](#cam41879-bib-0021){ref-type="ref"} As incident HPV detection is negatively associated with viral load as well as with repeat detection, this suggests that actual new acquisition of HPV is less common than reactivation or intermittent persistence.

The role of naturally acquired antibodies in the prevention of new infections and cervical abnormalities can be explored in the control arms of large HPV vaccine trials. A correlation between naturally acquired antibodies to HPV‐16 (and to a lesser extent HPV‐18) and reduced risk of newly detected infection was demonstrated in younger women (15‐25 years) in the control arm of the PApilloma TRIal against Cancer In young Adults (PATRICIA; NCT00122681).[12](#cam41879-bib-0012){ref-type="ref"} Here, we examined the risk of "newly" detected HPV infections and cervical abnormalities among women \>25 years in relation to naturally acquired HPV‐16/18 antibodies in the control arm of the VIVIANE during a 7‐year follow‐up period.[22](#cam41879-bib-0022){ref-type="ref"}, [23](#cam41879-bib-0023){ref-type="ref"}

Our aim was to assess whether the risk factors for HPV infection differed between seropositive and seronegative women. We also analyzed risk factors stratified by baseline serostatus to mitigate the limitations in differentiating between new and reactivated infections.

2. METHODS {#cam41879-sec-0006}
==========

2.1. Study participants and procedures {#cam41879-sec-0007}
--------------------------------------

Women aged \>25 years were included in the control arm of the multinational, VIVIANE trial and were followed up for seven years. VIVIANE is the Human Papilloma Virus: Vaccine Immunogenicity and Efficacy trial. This is a phase 3 double‐blind, controlled vaccine trial based on age, cytology, region, and serostatus.[23](#cam41879-bib-0023){ref-type="ref"} The methodology of VIVIANE has been presented in detail elsewhere.[24](#cam41879-bib-0024){ref-type="ref"}

Our analysis included women DNA‐negative for HPV‐16 and −18 at Month 0, with normal or low‐grade cytology (ie, negative or atypical squamous cells of undetermined significance \[ASC‐US\] or low‐grade squamous intraepithelial lesion \[LSIL\]) at Month 0, who had received at least one control vaccine dose (Al\[OH\]~3~) and who had sexual intercourse before or during the follow‐up (Figure [1](#cam41879-fig-0001){ref-type="fig"}).

![Flowcharts. HPV, human papillomavirus; TVC, total vaccinated cohort; N, number of women; Sero+, women seropositive for HPV‐16/18; Sero −, women seronegative for HPV‐16/18](CAM4-8-4938-g001){#cam41879-fig-0001}

Serum anti‐HPV‐16/18 antibodies were determined by enzyme‐linked immunosorbent assay (ELISA) from blood samples collected at baseline and every 12 months thereafter. Seropositivity was defined as an antibody level greater than or equal to the assay cutoff which was 8 ELISA units (EU)/mL for HPV‐16 and 7 EU/mL for HPV‐18.[25](#cam41879-bib-0025){ref-type="ref"}

Liquid‐based cytology samples were tested for HPV using DNA typing PCR‐based assays every six months and cytopathological examinations every12 months.[25](#cam41879-bib-0025){ref-type="ref"} Information on known risk factors that predispose women to HPV cervical infection or recognized cofactors for cervical carcinogenesis was also collected through questionnaires. These data were collected at study entry and included demographic information, smoking habits, past and current sexual history, and reproductive status. In addition, data on participants\' sexual behavior and use of contraception were collected every six months up to month 48.

Written informed consent was obtained from each woman before any study‐specific procedures were implemented. The protocol and other materials were approved by a national, regional, or investigational center Independent Ethics Committee or Institutional Review Board. The trial was conducted based on the Code of Ethics of the World Medical Association (Declaration of Helsinki).

The endpoints included in these analyses were (a) newly detected HPV‐16 and HPV‐18 incident infections, (b) 6‐ and 12‐month persistent infection (PI), ASC‐US+, and (c) histopathologically confirmed cervical intraepithelial neoplasia grade 1 or greater (CIN1+ and CIN2+). HPV‐16 and HPV‐18 serostatus were the main exposure variables.

2.2. Statistics {#cam41879-sec-0008}
---------------

The analyses were performed on the total vaccinated cohort (TVC) of the control arm of the VIVIANE trial and included all women who received at least one control vaccine dose, who were DNA‐negative for HPV‐16 and HPV‐18 at Month 0, and who also had a normal or low‐grade cytology (ie, negative or ASC‐US or LSIL) at Month 0. All analyses were performed on women who had ever had sexual intercourse before study entry or during the follow‐up period.

Analyses were performed using SAS version 9.2. The incidence rate (IR) was calculated as the number of incident events divided by the total person‐time. Person‐years were calculated as the sum of the follow‐up for each participant expressed in years. The follow‐up period started on the day after first vaccination (control vaccine) and ended on the first occurrence of the endpoint or the last visit (whichever occurred first). The relationship between the exposure variables and the risk of newly detected infections or cervical abnormalities was assessed using Cox proportional hazard models. Univariate analyses were done to obtain unadjusted hazard ratios of the determinants of interest (not shown). For each endpoint, the following multivariable Cox models were performed including: the type‐specific serostatus at baseline as a binary variable;the type‐specific serostatus as a binary time‐dependent variable;the antibody level as a time‐dependent continuous variable;log‐transformed antibody level as a time‐dependent continuous variable.

For each endpoint, we included nine covariates in these models: region, age at inclusion, age at first sexual intercourse, marital status, smoking status at baseline, number of sexual partners during the past year, previous pregnancy, history of *Chlamydia trachomatis* infection, history of HPV infection/treatment or nonintact cervix. HPV‐associated infection or treatment was defined as two or more abnormal smears in sequence, an abnormal colposcopy or biopsy, or treatment of the cervix after abnormal smear or colposcopy findings. The histories of HPV infection/treatment were collected at baseline using medical history.

For ASC‐US+ only, previous type‐specific HPV infection was included as a time‐dependent variable since the presence of these cells indicates an active infection at a specific point in time. For CIN1+ and CIN2+ endpoints, no inferential analyses were performed due to the low number of cases. Also, analyses of determinants of interest were performed separately for the baseline seronegative and seropositive subjects to help determine whether newly detected infections were new or had been reactivated. The analysis is based on two assumptions: (a) An association between a latent reactivated infection and a known risk factor should be weaker than an association between a new infection and a known risk factor. (b) The reactivation of a PI should be more frequent in the baseline seropositive (representing presumed prior HPV infection exposure) subjects than in the baseline seronegative (representing presumed naïve, absent prior HPV infection exposure) subjects.

3. RESULTS {#cam41879-sec-0009}
==========

3.1. Study population {#cam41879-sec-0010}
---------------------

In total, 2687 and 2705 participants were included in the analysis of HPV‐16 and HPV‐18 endpoints, respectively (Figure [1](#cam41879-fig-0001){ref-type="fig"}). There was a difference of 3% between HPV‐16/18 by serostatus at baseline. Seroprevalence at enrollment was 31% (828/2687 seropositive women) for HPV‐16 and 28% (756/2705 seropositive women) for HPV‐18 (Table [1](#cam41879-tbl-0001){ref-type="table"}). This difference is entirely in agreement with the well‐known higher prevalence of 16 than 18 in HPV infections.

###### 

Frequency distributions of exposure variables and risk factors at study entry ‐ TVC‐Control arm‐excluding high grade or missing cytology at Month 0 -- Ever had sexual intercourse

                                                                                                                                Overall (N = 2785)   Baseline HPV‐16 serostatus (N = 2687)   Baseline HPV‐18 serostatus (N = 2705)                                                   
  ---------------------------------------------------------------------- ------------------------------------------------------ -------------------- --------------------------------------- --------------------------------------- ------- ------- ------- ------- ------- ------- -------
  Marital status                                                         Living or Lived with partner                           2354                 84.52                                   1629                                    87.63   659     79.59   1677    86.04   618     81.75
  Single                                                                 430                                                    15.44                230                                     12.37                                   169     20.41   271     13.90   138     18.25   
  Missing                                                                1                                                      0.04                                                                                                                 1       0.05                    
  Number of pack years                                                   \[0; 0.5\]                                             2016                 72.39                                   1415                                    76.12   549     66.30   1451    74.45   514     67.99
  ≥0.5                                                                   757                                                    27.18                439                                     23.61                                   273     32.97   493     25.30   237     31.35   
  Missing                                                                12                                                     0.43                 5                                       0.27                                    6       0.72    5       0.26    5       0.66    
  Smoking status at baseline                                             No                                                     2398                 86.10                                   1639                                    88.17   688     83.09   1702    87.33   631     83.47
  Yes                                                                    386                                                    13.86                220                                     11.83                                   140     16.91   246     12.62   125     16.53   
  Missing                                                                1                                                      0.04                 .                                                                               .               1       0.05    .               
  Sexual history at study entry                                          No                                                     5                    0.18                                    4                                       0.22    1       0.12    4       0.21    1       0.13
  Yes                                                                    2779                                                   99.78                1855                                    99.78                                   827     99.88   1944    99.74   755     99.87   
  Missing                                                                1                                                      0.04                 .                                                                               .               1       0.05    .               
  History of HPV -- Infection/treatment or not intact cervix             No                                                     2431                 87.29                                   1674                                    90.05   685     82.73   1725    88.51   636     84.13
  Yes                                                                    354                                                    12.71                185                                     9.95                                    143     17.27   224     11.49   120     15.87   
  Age at first sexual intercourse (years)                                \<15                                                   141                  5.06                                    66                                      3.55    67      8.09    73      3.75    59      7.80
  15--17                                                                 899                                                    32.28                507                                     27.27                                   354     42.75   557     28.58   309     40.87   
  18--25                                                                 1561                                                   56.05                1137                                    61.16                                   377     45.53   1173    60.18   354     46.83   
  \>26                                                                   177                                                    6.36                 146                                     7.85                                    27      3.26    141     7.23    32      4.23    
  Missing                                                                7                                                      0.25                 3                                       0.16                                    3       0.36    5       0.26    2       0.26    
  Number of lifetime sexual partners                                     0                                                      5                    0.18                                    4                                       0.22    1       0.12    4       0.21    1       0.13
  1                                                                      1068                                                   38.35                876                                     47.12                                   174     21.01   864     44.33   183     24.21   
  2--5                                                                   1017                                                   36.52                666                                     35.83                                   310     37.44   703     36.07   286     37.83   
  6--10                                                                  361                                                    12.96                177                                     9.52                                    167     20.17   214     10.98   130     17.20   
  11--15                                                                 146                                                    5.24                 68                                      3.66                                    69      8.33    79      4.05    60      7.94    
  16--20                                                                 67                                                     2.41                 23                                      1.24                                    41      4.95    30      1.54    35      4.63    
  \>20                                                                   120                                                    4.31                 45                                      2.42                                    66      7.97    54      2.77    61      8.07    
  Missing                                                                1                                                      0.04                 .                                       .                                                       1       0.05    .               
  Number of sexual partners during the last year                         0                                                      301                  10.81                                   195                                     10.49   96      11.59   214     10.98   85      11.24
  1                                                                      2219                                                   79.68                1533                                    82.46                                   623     75.24   1585    81.32   574     75.93   
  2‐3                                                                    230                                                    8.26                 115                                     6.19                                    95      11.47   132     6.77    83      10.98   
  ≥4                                                                     34                                                     1.22                 16                                      0.86                                    14      1.69    17      0.87    14      1.85    
  Missing                                                                1                                                      0.04                                                                                                                 1       0.05                    
  At least one previous pregnancy                                        No                                                     439                  15.76                                   277                                     14.90   138     16.67   299     15.34   119     15.74
  Yes                                                                    2345                                                   84.20                1582                                    85.10                                   690     83.33   1649    84.61   637     84.26   
  Missing                                                                1                                                      0.04                                                                                                                 1       0.05                    
  *Chlamydia trachomatis*                                                No                                                     2626                 94.29                                   1794                                    96.50   741     89.49   1862    95.54   693     91.67
  Yes                                                                    133                                                    4.78                 56                                      3.01                                    72      8.70    70      3.59    55      7.28    
  Missing                                                                26                                                     0.93                 9                                       0.48                                    15      1.81    17      0.87    8       1.06    
  Contraception during lifetime[a](#cam41879-note-0002){ref-type="fn"}   No contraception                                       413                  14.83                                   298                                     16.03   102     12.32   297     15.24   110     14.55
                                                                         Hormonal use for contraception or another indication   1802                 24.85                                   1139                                    61.27   596     71.98   1220    62.60   515     68.12
                                                                         Intra‐Uterine Device                                   692                  25.96                                   477                                     25.66   193     23.31   501     25.71   172     22.75
                                                                         Sterilized                                             723                  35.30                                   498                                     26.79   204     24.64   522     26.78   183     24.21
  Menopausal Status                                                      Premenopausal                                          2448                 87.90                                   1636                                    88.00   721     87.08   1717    88.10   657     86.90
                                                                         Perimenopausal                                         180                  6.46                                    116                                     6.24    60      7.25    117     6.00    59      7.80
                                                                         Postmenopausal                                         142                  5.10                                    93                                      5.00    46      5.56    101     5.18    39      5.16
                                                                         Missing                                                15                   0.54                                    14                                      0.75    1       0.12    14      0.72    1       0.13

N = total Number of subjects with a given group.

A subject can be included in more than one category.

John Wiley & Sons, Ltd

Among those seropositive at enrollment, the geometric mean antibody concentration was 38.3 EU/mL (range: 8‐2527) and 23.3 EU/mL (range: 7‐725) for HPV‐16 and HPV‐18, respectively.

At enrollment, 45% of women were 26‐35 years old, 44% were 36‐45 years old, and 11% were ≥46 years old. Nearly all participants had been previously sexually active at the start of the study, except five who had their first sexual intercourse during the follow‐up. 56% had started sexual activity between 18 and 25 years (32% between 15 and 17), 80% had had one sexual partner during the previous year, and 84% had had a previous pregnancy. Moreover, 14% of women were current smokers, 5% were *C trachomatis*‐positive, and 87.8% were classified as pre‐menopausal, 6.5% as peri‐menopausal, 5.1% as post‐menopausal, while the status for the remaining 0.5% was missing.

3.2. Incidence rates of the endpoints {#cam41879-sec-0011}
-------------------------------------

The IR per 100 person‐years of newly detected infections was 1.07 (95% confidence interval \[CI\]: 0.91‐1.25) for HPV‐16 and 0.64 (0.52‐0.78) for HPV‐18. For 6‐month PI, the IRs were 0.56 (0.44‐0.69) for HPV‐16 and 0.23 (0.16‐0.32) for HPV‐18. For 12‐month PI, these were 0.30 (0.22‐0.40) for HPV‐16 and 0.13 (0.08‐0.20) for HPV‐18.

The IRs for ASC‐US+ were 0.34 (0.26‐0.45) for HPV‐16 and 0.21 (0.14‐0.30) for HPV‐18.

During the seven years of follow‐up, 13 new HPV‐16 CIN1+ cases, 14 HPV‐18 CIN1+ cases, 8 HPV‐16 CIN2+ cases, and 9 HPV‐18 CIN2+ cases were detected.

3.3. Multivariable models {#cam41879-sec-0012}
-------------------------

The multivariable Cox proportional hazard model, including the serostatus at baseline as a binary variable, showed that the risk of newly detected HPV‐16, 6‐month PI and ASC‐US+ was statistically significantly lower in seropositive vs seronegative women (hazard ratio \[HR\] = 0.56 \[0.32‐0.99; *P* = 0.04\] and 0.28 \[0.12‐0.67; *P* = 0.004\], respectively; Table [2](#cam41879-tbl-0002){ref-type="table"}). Analysis for HPV‐16 incident infections and 12‐month PI also showed a somewhat lower risk in seropositive than seronegative women although the difference was not statistically significant (HR = 0.81 \[0.56‐1.16; *P* = 0.26\] and 0.53 \[0.24‐1.16; *P* = 0.11\], respectively). With regard to HPV‐18, we found the risk of newly detected infections and cervical abnormalities was lower in seropositive vs seronegative women, but not statistically significant (HR = 0.95 \[0.59‐1.51; *P* = 0.82\] for incident infections, 0.43 \[0.16‐1.13; *P* = 0.09\] for 6‐month PI, 0.31 \[0.07‐1.36; *P* = 0.12\] for 12‐month PI, and 0.61 \[0.23‐1.61; *P* = 0.32\] for ASC‐US+; Table [3](#cam41879-tbl-0003){ref-type="table"}). Other determinants (Tables [2](#cam41879-tbl-0002){ref-type="table"} and [3](#cam41879-tbl-0003){ref-type="table"}, and Supplementary Tables) associated with a higher risk of new infections were ≥2 sexual partners during the past year (for incident HPV‐16 and HPV‐18 infections, and 6‐month and 12‐month HPV‐16 and HPV‐18 PI), being single (for incident HPV‐18 infections), a history of HPV infection/treatment, or having a nonintact cervix (for incident HPV‐16 and HPV‐18 infections). Women older than 35 years at enrollment had a lower risk of incident HPV‐16 infections as well as HPV‐18 incident infections, 6‐month PI, and ASC‐US+. The risk of infections varied significantly among geographical regions. The risk factors associated with ASC‐US+ were a history of HPV infection/treatment, a nonintact cervix (for HPV‐18), and a previous type‐specific HPV infection (for HPV‐16 and HPV‐18).

###### 

Multivariable Cox model for HPV‐16 newly detected infections and cervical abnormalities including serostatus at baseline

  Risk factor                                               Category                       Enrollment serostatus (binary)                                                                                                                                                                                                                                   
  --------------------------------------------------------- ------------------------------ -------------------------------- -------------------------- ------------ --------- -------- --------------------------- ------------ --------- ------- --------------------------- ------------ --------- -------- ------------------------------- ------------- ---
  HPV‐16 serostatus                                         Negative                       1814                             114                        1            ‐         1779     67                          1            *‐*       1755    38                          1            *‐*       1787     43                              1             ‐
  Positive                                                  790                            45                               0.81 (0.56‐1.16)           0.2559       767       17       **0.56 (0.32**‐**0.99)**    **0.0446**   753       8       0.53 (0.24‐1.16)            0.1123       **774**   **9**    **0.28 (0.12‐0.67)**            **0.0043**    
  Age at inclusion                                          26‐35                          1157                             94                         1            ‐         1134     45                          1            *‐*       1109    21                          1            *‐*       1139     33                              1             ‐
  ≥36                                                       **1157**                       **65**                           **0.58 (0.42**‐**0.82)**   **0.0016**   1412      39       0.78 (0.50‐1.24)            0.2946       1399      25      0.99 (0.54‐1.82)            0.9817       1423      19       0.57 (0.31‐1.03)                0.0640        
  Region                                                    Europe                         505                              22                         1            ‐         495      6                           1            ‐         491     5                           1            ‐         500      8                               1             ‐
  Asia Pacific                                              779                            38                               1.19 (0.68‐2.08)           0.5445       **772**   **23**   **2.57 (1.01**‐**6.52)**    **0.0476**   765       15      1.75 (0.61‐5.05)            0.3004       772       10       0.77 (0.28‐2.10)                0.6065        
  Latin America                                             679                            43                               1.56 (0.90‐2.71)           0.1142       **663**   **29**   **3.86 (1.54**‐**9.70)**    **0.0040**   658       16      2.26 (0.79‐6.48)            0.1308       666       18       1.66 (0.65‐4.21)                0.2862        
  North America                                             **641**                        **56**                           **2.38 (1.42**‐**3.97)**   **0.0009**   **616**   **26**   **4.28 (1.74**‐**10.54)**   **0.0015**   594       10      1.89 (0.63‐5.66)            0.2575       623       16       1.32 (0.50‐3.46)                0.5716        
  Age at first sexual intercourse grouped                   ≥18                            1654                             98                         1            ‐         1621     57                          1            ‐         1600    33                          1            ‐         1630     32                              1             ‐
  15‐17                                                     817                            50                               0.85 (0.58‐1.23)           0.3775       799       57       0.62 (0.36‐1.09)            0.0967       784       9       0.56 (0.26‐1.22)            0.1473       804       14       1.05 (0.53‐2.08)                0.8832        
  \<15                                                      127                            11                               1.08 (0.56‐2.07)           0.8271       120       8        1.48 (0.67‐3.27)            0.3329       118       4       1.30 (0.43‐3.95)            0.6433       121       6        2.20 (0.79‐6.16)                0.1322        
  Marital status at baseline                                Living or lived with partner   2227                             129                        1            ‐         2177     69                          1            ‐         2151    41                          1            ‐         2190     44                              1             ‐
  Single                                                    377                            30                               0.79 (0.49‐1.29)           0.3493       369       15       0.89 (0.46‐1.75)            0.7434       357       5       0.70 (0.24‐2.04)            0.5116       371       8        0.67 (0.27‐1.67)                0.3878        
  Smoking status at baseline                                No                             2264                             131                        1            ‐         2221     72                          1            *‐*       2192    40                          1            *‐*       2229     40                              1             ‐
  Yes                                                       340                            28                               1.35 (0.88‐2.06)           0.1701       325       12       1.15 (0.61‐2.17)            0.6678       316       6       1.10 (0.45‐2.70)            0.8278       332       12       1.78 (0.89‐3.59)                0.1049        
  Number of sexual partners during the last year            0                              283                              16                         1            ‐         277      8                           1            ‐         272     2                           1            ‐         279      5                               1             ‐
  1                                                         2096                           112                              0.88 (0.52‐1.52)           0.6563       2052      59       1.02 (0.48‐2.18)            0.9634       2026      35      2.26 (0.54‐9.57)            0.2663       2064      36       0.89 (0.33‐2.35)                0.8105        
  ≥2                                                        **225**                        **31**                           **2.36 (1.26**‐**4.44)**   **0.0074**   **217**   **17**   **3.53 (1.47**‐**8.48)**    **0.0048**   **210**   **9**   **8.20 (1.70**‐**39.49)**   **0.0087**   218       11       1.72 (0.56‐5.28)                0.3399        
  Pregnancy                                                 No                             401                              35                         1            ‐         393      19                          1            ‐         384     7                           1            ‐         394      11                              1             ‐
  Yes                                                       2203                           124                              0.74 (0.47‐1.14)           0.1732       2153      65       0.57 (0.31‐1.05)            0.0696       2124      39      0.82 (0.33‐2.06)            0.6793       2167      41       0.91 (0.40‐2.06)                0.8211        
  *Chlamydia* infection at baseline                         No                             2458                             150                        1            ‐         2407     81                          1            ‐         2371    44                          1            ‐         2420     48                              1             ‐
  Yes                                                       122                            7                                0.59 (0.27‐1.29)           0.1848       115       2        0.36 (0.08‐1.51)            0.1618       113       2       0.95 (0.21‐4.32)            0.9486       117       3        2.57 (0.71‐9.27)                0.1483        
  History of HPV infection/treatment or not intact cervix   No                             2285                             128                        1            ‐         2234     72                          1            ‐         2202    39                          1            ‐         2246     3                               1             ‐
  Yes                                                       **319**                        **31**                           **1.56 (1.03**‐**2.35)**   **0.0348**   312       12       1.17 (0.62‐2.18)            0.6316       306       7       1.31 (0.57‐3.02)            0.5240       315       8        1.03 (0.45‐2.36)                0.9416        
  Previous HPV‐16 infection                                 No                                                                                         ‐            ‐                                              ‐            ‐                                             ‐            ‐         2561     24                              1             ‐
  Yes                                                                                                                       ‐                          ‐                               ‐                           ‐                              ‐                           ‐            **128**   **28**   **122.89 (67.91**‐**222.37)**   **\<.0001**   

HPV = human papillomavirus; PI = persistent infection; CI = confidence interval; ACS‐US+ = atypical squamous cell of undetermined significance or greater; N = total number of subjects; n = number of cases reported. Bold: *P*‐values \<0.05

John Wiley & Sons, Ltd

###### 

Multivariable Cox model for HPV‐18 newly detected infections and cervical abnormalities including serostatus at baseline

  Risk factor                                               Category                       Enrollment serostatus (binary)                                                                                                                                                                                                                    
  --------------------------------------------------------- ------------------------------ -------------------------------- -------------------------- ------------- ---------- ------- -------------------------- ------------ ------ ------ ------------------- -------- ---------- -------- ------------------------------- ------------- ---
  HPV‐18 serostatus                                         Negative                       1907                             97                         1             ‐          1874    31                         1            *‐*    1840   18                  1        ‐          1882     26                              1             ‐
  Positive                                                  713                            25                               0.95 (0.59‐1.51)           0.8165        689        5       0.43 (0.16‐1.13)           0.0883       681    2      0.31 (0.07‐1.36)    0.1198   696        6        0.61 (0.23‐1.61)                0.3176        
  Age at inclusion                                          26‐35                          1156                             70                         1             ‐          1133    28                         1            *‐*    1108   15                  1        ‐          1137     25                              1             ‐
  ≥36                                                       **1464**                       **27**                           **0.35 (0.22**‐**0.56)**   **\<.0001**   **1430**   **8**   **0.29 (0.13**‐**0.65)**   **0.0029**   1413   5      0.39 (0.13‐1.15)    0.0863   **1441**   **7**    **0.32 (0.13**‐**0.77)**        **0.0115**    
  Region                                                    Europe                         518                              19                         1             ‐          508     6                          1            ‐      502    7                   1        ‐          513      5                               1             ‐
  Asia Pacific                                              775                            28                               1.22 (0.65‐2.32)           0.5361        768        9       1.32 (0.41‐4.24)           0.6364       761    6      1.70 (0.38‐7.60)    0.4907   768        7        1.16 (0.31‐4.36)                0.8207        
  Latin America                                             688                            23                               1.14 (0.58‐2.21)           0.7049        672        8       1.35 (0.41‐4.45)           0.6178       666    3      0.98 (0.18‐5.43)    0.9834   675        11       3.04 (0.82‐11.25)               0.0964        
  North America                                             639                            27                               1.12 (0.60‐2.09)           0.7281        615        13      2.06 (0.71‐5.98)           0.1837       592    7      1.99 (0.49‐8.13)    0.3378   622        9        2.70 (0.73‐9.97)                0.1371        
  Age at first sexual intercourse grouped                   ≥18                            1666                             67                         1             ‐          1633    23                         1            ‐      1610   14                  1        ‐          1642     23                              1             ‐
  15‐17                                                     821                            31                               0.96 (0.59‐1.55)           0.8591        804        12      0.81 (0.37‐1.78)           0.6062       787    6      0.71 (0.24‐2.09)    0.5349   809        6        0.41 (0.15‐1.12)                0.0818        
  \<15                                                      126                            9                                1.57 (0.74‐3.34)           0.2430        119        1       0.37 (0.05‐2.91)           0.3439       117    0      Not estimated       ‐        120        3        1.82 (0.46‐7.24)                0.3945        
  Marital status at baseline                                Living or lived with partner   2234                             67                         1             ‐          2185    24                         1            ‐      2156   12                  1        ‐          2198     22                              1             ‐
  Single                                                    **385**                        **30**                           **2.13 (1.22**‐**3.71)**   **0.0076**    377        12      1.96 (0.79‐4.86)           0.1452       364    8      2.79 (0.82‐9.48)    0.1010   379        10       1.66 (0.58‐4.71)                0.3426        
  Smoking status at baseline                                No                             2270                             82                         1             ‐          2228    29                         1            *‐*    2196   16                  1        ‐          2236     28                              1             ‐
  Yes                                                       349                            15                               0.88 (0.49‐1.58)           0.6754        334        7       1.33 (0.56‐3.14)           0.5190       324    4      1.43 (0.45‐4.51)    0.5416   341        4        0.78 (0.26‐2.35)                0.6547        
  Number of sexual partners during the last year            0                              291                              7                          1             ‐          285     2                          1            ‐      280    2                   1        ‐          287      3                               1             ‐
  1                                                         2097                           68                               1.46 (0.65‐3.26)           0.3565        2054       25      1.85 (0.42‐8.16)           0.4151       2026   13     1.09 (0.22‐5.27)    0.9169   2066       23       1.23 (0.34‐4.36)                0.7530        
  ≥2                                                        **231**                        **22**                           **3.28 (1.36**‐**7.88)**   **0.0080**    223        9       4.69 (0.97‐22.56)          0.0540       214    5      2.92 (0.53‐16.23)   0.2197   224        6        1.57 (0.35‐7.15)                0.5589        
  Pregnancy                                                 No                             404                              21                         1             ‐          396     9                          1            ‐      386    6                   1        ‐          397      8                               1             ‐
  Yes                                                       2215                           76                               1.17 (0.66‐2.06)           0.5931        2166       27      1.14 (0.46‐2.83)           0.7715       2134   14     1.03 (0.32‐3.35)    0.9621   2180       24       0.96 (0.32‐2.87)                0.9462        
  *Chlamydia* infection at baseline                         No                             2477                             89                         1             ‐          2427    33                         1            ‐      2388   18                  1        ‐          2440     30                              1             ‐
  Yes                                                       118                            6                                0.82 (0.34‐1.96)           0.6579        111        2       0.80 (0.18‐3.52)           0.7643       109    1      0.73 (0.09‐5.82)    0.7666   113        1        0.27 (0.03‐2.53)                0.2534        
  History of HPV infection/treatment or not intact cervix   No                             2285                             75                         1             ‐          2236    27                         1            ‐      2203   1                   1        ‐          2248     22                              1             ‐
  Yes                                                       **335**                        **22**                           **1.72 (1.03**‐**2.86)**   **0.0373**    327        9       1.79 (0.79‐4.09)           0.1658       318    5      1.64 (0.52‐5.20)    0.3980   **330**    **10**   **2.57 (1.10**‐**6.01)**        **0.0288**    
  Previous cervical HPV‐18 infection                        No                                                                                         ‐             ‐                                             ‐            ‐                                 ‐        ‐          2578     20                              1             ‐
  Yes                                                                                                                       ‐                          ‐                                ‐                          ‐                          ‐                   ‐        **68**     **12**   **122.93 (54.69**‐**276.33)**   **\<.0001**   

HPV = human papillomavirus; PI = persistent infection; CI = confidence interval; ACS‐US+ = atypical squamous cell of undetermined significance or greater; N = total number of subjects; n = number of cases reported. Bold: *P*‐values \<0.05
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The other multivariable Cox proportional hazard models (including the serostatus as a time‐dependent variable, antibody level as a time‐dependent variable, and log‐transformed level as a time‐dependent variable) showed similar results (Figure [2](#cam41879-fig-0002){ref-type="fig"} and Supplementary Tables).

![Risk ratio of incident, 6‐mo persistent, and 12‐mo persistent infection and atypical squamous cell of undetermined significance or greater in HPV‐16/HPV‐18 type‐specific seropositive vs seronegative women. Error bars represent 95% confidence intervals; ^\#^95% confidence intervals are narrow and not visible; HPV, human papillomavirus; PI, persistent infection; bin, binary; ab, antibody; ACS‐US+, atypical squamous cell of undetermined significance or greater](CAM4-8-4938-g002){#cam41879-fig-0002}

The analyses stratified by baseline serostatus showed that these risk factors (number of sexual partners in the last 12 months, living single and smoking) were more marked in seronegative than in seropositive women (Table [4](#cam41879-tbl-0004){ref-type="table"}).

###### 

Multivariable Cox model for HPV‐16 and HPV‐18 6‐mo persistent infection and incident infection according to different serostatus at baseline

  Risk factor                                               HPV‐16 6‐mo PI              HPV‐18 6‐mo PI   HPV‐16 incident infection   HPV‐18 incident infection                                                                                                                                                                                                                
  --------------------------------------------------------- --------------------------- ---------------- --------------------------- --------------------------- -------------------------- ------------ ---------------------- -------- ---------------------- ------------ ---------------------- ------------ ---------------------- ------------- ----------------------- ------------
  Age at inclusion                                                                                                                                                                                                                                                                                                                                                            
  26‐35                                                     1                           ‐                1                           ‐                           1                          ‐            1                      ‐        1                      ‐            1                      ‐            1                      ‐             1                       ‐
  ≥36                                                       0.73 (0.44‐1.22)            0.2306           1.27 (0.43‐3.74)            0.6625                      **0.33 (0.14**‐**0.77)**   **0.0103**   Not estimated          ‐        **0.62 (0.42‐0.92)**   **0.0177**   **0.51 (0.27‐0.97)**   **0.0409**   **0.33 (0.19‐0.57)**   **\<0.001**   0.41 (0.17‐1.01)        0.0527
  Region                                                                                                                                                                                                                                                                                                                                                                      
  Europe                                                    1                           ‐                1                           ‐                           1                          ‐            1                      ‐        1                      ‐            1                      ‐            1                      ‐             1                       ‐
  Asia Pacific                                              2.70 (0.88‐8.29)            0.0825           2.79 (0.50‐15.71)           0.2447                      1.16 (0.35‐3.81)           0.8069       Not estimated          ‐        1.13 (0.59‐2.13)       0.7172       1.25 (0.37‐4.21)       0.7169       1.06 (0.48‐2.31)       0.8893        1.85 (0.57‐5.95)        0.3033
  Latin America                                             **5.00 (1.66**‐**15.02)**   **0.0042**       1.33 (0.18‐10.04)           0.7804                      0.83 (0.23‐2.95)           0.7750       Not estimated          ‐        1.46 (0.77‐2.76)       0.2433       2.03 (0.65‐6.36)       0.2225       1.07 (0.49‐2.33)       0.8717        1.41 (0.38‐5.25)        0.6131
  North America                                             **5.27 (1.77**‐**15.73)**   **0.0029**       2.80 (0.58‐13.52)           0.2002                      1.74 (0.57‐5.28)           0.3319       Not estimated          ‐        **2.27 (1.24‐4.17)**   **0.0081**   **2.76 (1.03‐7.43)**   **0.0445**   1.44 (0.69‐3.00)       0.3268        0.59 (0.18‐2.01)        0.4022
  Age at first sexual intercourse grouped                                                                                                                                                                                                                                                                                                                                     
  ≥18                                                       1                           ‐                1                           ‐                           1                          ‐            1                      ‐        1                      ‐            1                      ‐            1                      ‐             1                       ‐
  15‐17                                                     0.58 (0.30‐1.09)            0.0915           0.67 (0.20‐2.29)            0.5274                      0.67 (0.28‐1.60)           0.3669       5.52 (0.37‐81.42)      0.2133   0.81 (0.52‐1.26)       0.3457       0.88 (0.43‐1.81)       0.7343       0.97 (0.56‐1.68)       0.9072        0.79 (0.29‐2.15)        0.6378
  \<15                                                      0.86 (0.29‐2.55)            0.7829           **4.04 (1.06**‐**15.47)**   **0.0413**                  Not estimated              ‐            29.71 (0.70‐1263.78)   0.0763   0.58 (0.20‐1.64)       0.3042       1.77 (0.69‐4.54)       0.2372       0.78 (0.23‐2.63)       0.6868        **3.58 (1.19‐10.83)**   **0.0237**
  Marital status at baseline                                                                                                                                                                                                                                                                                                                                                  
  Living or lived with partner                              1                           ‐                1                           ‐                           1                          ‐            1                      ‐        1                      ‐            1                      ‐            1                      ‐             1                       ‐
  Single                                                    0.97 (0.45‐2.11)            0.9381           0.87 (0.22‐3.46)            0.8395                      1.93 (0.70‐5.36)           0.2039       2.73 (0.20‐36.42)      0.4484   0.75 (0.42‐1.37)       0.3537       1.02 (0.45‐2.30)       0.9587       1.93 (1.00‐3.73)       0.0514        2.64 (0.93‐7.44)        0.0672
  Smoking status at baseline                                                                                                                                                                                                                                                                                                                                                  
  No                                                        1                           ‐                1                           ‐                           1                          ‐            1                      ‐        1                      ‐            1                      ‐            1                      ‐             1                       ‐
  Yes                                                       1.36 (0.68‐2.74)            0.3825           0.68 (0.15‐3.17)            0.6283                      1.40 (0.55‐3.58)           0.4801       0.84 (0.07‐9.42)       0.8874   **1.75 (1.07‐2.86)**   **0.0247**   0.72 (0.29‐1.74)       0.4633       1.03 (0.59‐3.92)       0.9385        0.57 (0.16‐1.98)        0.3747
  Number of sexual partners during the last year                                                                                                                                                                                                                                                                                                                              
  0                                                         1                           ‐                1                           ‐                           1                          ‐            1                      ‐        1                      ‐            1                      ‐            1                      ‐             1                       ‐
  1                                                         1.08 (0.45‐2.59)            0.8652           0.72 (0.15‐3.52)            0.6853                      1.58 (0.35‐7.15)           0.5522       Not estimated          ‐        0.84 (0.45‐1.57)       0.5839       0.99 (0.34‐2.92)       0.9919       1.52 (0.59‐3.92)       0.3916        1.33 (0.28‐6.22)        0.7199
  ≥2                                                        **4.49 (1.62**‐**12.49)**   **0.0039**       2.04 (0.33‐12.59)           0.4428                      4.51 (0.90‐22.75)          0.0679       Not estimated          ‐        **2.60 (1.23‐5.50)**   **0.0127**   1.98 (0.59‐6.69)       0.2704       **3.36 (1.18‐9.63)**   **0.0238**    3.36 (0.67‐16.91)       0.1419
  Pregnancy                                                                                                                                                                                                                                                                                                                                                                   
  No                                                        1                           ‐                1                           ‐                           1                          ‐            1                      ‐        1                      ‐            1                      ‐            1                      ‐             1                       ‐
  Yes                                                       0.59 (0.30‐1.19)            0.1396           0.57 (0.15‐2.22)            0.4207                      1.74 (0.60‐5.01)           0.3044       0.10 (0.01‐1.72)       0.1119   **0.60 (0.36‐1.01)**   **0.0127**   1.44 (0.57‐3.63)       0.4343       1.40 (0.70‐2.79)       0.3415        0.70 (0.25‐1.97)        0.4954
  *Chlamydia* infection at baseline                                                                                                                                                                                                                                                                                                                                           
  No                                                        1                           ‐                1                           ‐                           1                          ‐            1                      ‐        1                      ‐            1                      ‐            1                      ‐             1                       ‐
  Yes                                                       Not estimated               ‐                0.85 (0.18‐4.06)            0.8404                      0.59 (0.08‐4.55)           0.6120       1.97 (0.15‐26.31)      0.6071   0.17 (0.02‐1.22)       0.0777       1.09 (0.44‐2.72)       0.8547       0.73 (0.22‐2.45)       0.6094        1.03 (0.26‐4.12)        0.9658
  History of HPV infection/treatment or not intact cervix                                                                                                                                                                                                                                                                                                                     
  No                                                        1                           ‐                1                           ‐                           1                          ‐            1                      ‐        1                      ‐            1                      ‐            1                      ‐             1                       ‐
  Yes                                                       0.87 (0.39‐1.94)            0.7329           1.74 (0.58‐5.22)            0.3202                      2.10 (0.86‐5.13)           0.1024       0.76 (0.07‐8.56)       0.8229   1.36 (0.80‐2.32)       0.2582       1.89 (0.96‐3.71)       0.0648       1.82 (0.99‐3.35)       0.0530        1.19 (0.43‐3.30)        0.7309

HPV = human papillomavirus N = number of subjects used in the model; event = number of HPV‐type‐specific 6‐mo persistent cervical infection; PI = persistent infection; CI = confidence interval. Bold: *P*‐values \<0.05
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4. DISCUSSION {#cam41879-sec-0013}
=============

In this study, HPV‐16‐seropositive women of 25 years and older had a moderate decrease in risk of developing a new type‐specific HPV, PI, and ASC‐US+ compared to seronegative women. This result agrees with the hypothesis that naturally acquired HPV antibodies probably provide only partial protection against subsequent infection with the same HPV type. However, HPV‐18‐seropositive women had deficient levels of protection. Any naturally acquired protection afforded by either antibody is unlikely to be better than the benefits acquired by vaccination. Another study has found that women aged between 30 and 50 who were seropositive for high risk (HR) HPV at baseline had a higher incidence of new type‐specific HPV infection than women who were seronegative.[26](#cam41879-bib-0026){ref-type="ref"}

The association between seropositivity and the reduced risk of new infection was less in our study of 26+‐year‐old women than demonstrated in our study of younger women aged 15‐25 years in PATRICIA and in the Costa Rica Vaccine Trial.[12](#cam41879-bib-0012){ref-type="ref"}, [15](#cam41879-bib-0015){ref-type="ref"} This low protective effect or even absence of protective effect in \>25‐year‐old women could suggest waning of the natural immunity but it could also reflect reactivation of prior infection.[26](#cam41879-bib-0026){ref-type="ref"}

In the present study, we were not able to determine an accurate antibody threshold value for a defined reduction rate in infection. In the PATRICIA trial, HPV‐16 antibody levels comprised between 200 and 500 EU/mL were associated with a 90% reduction of incident infection, of 6‐month PI and of ASC‐US+.[12](#cam41879-bib-0012){ref-type="ref"} For HPV‐18, seropositivity was associated with a lower risk of ASC‐US+ and CIN1+ but no association was found between naturally acquired antibodies and new infection.[12](#cam41879-bib-0012){ref-type="ref"}

The current study also attempted to consider the change in serostatus during the follow‐up period. Including the serostatus as a time‐dependent variable and as a continuous variable in the Cox models is original. In a recent meta‐analysis, assessing the naturally acquired immunity against HPV infection, none of the 14 included studies considered the possible change of serostatus during the follow‐up period.[27](#cam41879-bib-0027){ref-type="ref"} Overall, our various models gave consistent results. However, the interpretation of the time‐dependent serostatus models can be challenging because of the interaction between the change in antibody titers and the incidence of new HPV infections. Because the serology was collected every 12 months and the cervical sample every six months, new, but undetected, infection could have boosted the antibody titer.

In another analysis of the control cohort of the VIVIANE trial, the risk of detecting CIN after natural HPV infection in women aged \>25 years was similar to that observed in women aged 15‐25 years from the PATRICIA trial.[24](#cam41879-bib-0024){ref-type="ref"} This observation suggests that there are little to no age‐related differences in the detection of natural HPV infection and their associated CIN lesions.

Our analysis of determinants when considered separately for the baseline seronegative and seropositive subjects partially supports the hypothesis suggested by other studies that most of the newly detected HPV infections in seropositive women would be a reactivation of prior HPV infections.[19](#cam41879-bib-0019){ref-type="ref"}, [20](#cam41879-bib-0020){ref-type="ref"}

The strengths of this study included the large cohort size of approximately 2700 women, and the relatively extended follow‐up period of seven years, which allowed for a thorough evaluation of an unvaccinated cohort. This study also had several limitations. A cervical sample test was performed only every six months, which could have meant that some incident HPV infections were not detected. In addition, it was not possible to determine whether an infection was quiescent, persistent at undetectable levels or was a new infection. Evidence exists that type‐specific HPV infection can present after a period of nondetection.[28](#cam41879-bib-0028){ref-type="ref"} Based on this assumption, some infections considered as new could indeed be a PI. This scenario could also bias the assessment of the relationship between natural antibodies and risk of new infection. Furthermore, the number of CIN1+ and CIN2+ cases was too low to allow for inferential analyses. Since we were unable to define which HPV type caused the abnormal cytology, ASC‐US+ lesions could ensue from non‐HPV‐16/18 types.

Further research is needed to better understand the natural history of HPV infection and the link between seropositivity and subsequent protection in women of different age groups.

In conclusion, multivariable Cox analyses showed evidence of lower risk of newly detected incident and persistent HPV infections and ASC‐US+ in women with naturally acquired antibodies against HPV‐16. The results for HPV‐18 are not conclusive since only a limited and nonsignificant decrease in risk was observed. These findings are consistent with a partial protective role of naturally acquired HPV antibodies against future infection with the corresponding HPV type. However, no threshold of antibody levels necessary for protection could be defined.
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